Abstract:2030 Background: Approximately 5% of advanced stage breast cancer (BC) will develop leptomeningeal disease, a rare form of metastasis in the meninges, a membrane surrounding the brain and spinal cord. The prognosis for BC-LMD is dismal and currently available treatments are ineffective. For example, intrathecal (IT) therapy such as trastuzumab, and proton cranial spinal radiotherapy have only showed modest success. Dendritic cells are a master regulator of the immune system and play a critical role in bridging the innate and adaptive immune response. Here, we used a novel preclinical model to administer MHC class II peptide-pulsed conventional Type 1 dendritic cells (cDC1s) intrathecally in mice that harbor either HER2+ or triple negative breast cancer (TBNC) LMD. Our murine BC-LMD murine data lead us to open a Phase 1 clinical trial of cDC1s in HER2+ and TNBC LMD (NCT05809752; in progress). Methods: Our lab developed a “murine Ommaya” which mimics the clinically used Ommaya reservoir and allows for repeated intrathecal (IT) injections of novel drugs at 3 – 7µl volume directly into the CSF. We next developed a pipeline for screening immunogenic MHC class II peptides from tumor-associated oncodrivers and using these targets to generate tumor-targeting cDC1s. We tested the resulting vaccines in a preclinical model that IT delivers peptide-pulsed cDC1 cell therapy directly into the BC-LMD microenvironment. Results: We tested the efficacy of treatment in HER2+ LMD and TNBC-LMD models and found effective responses; LMD mice that received IT cDC1 therapy exhibited reduced tumor burden and prolonged survival that was significantly better than systemic therapy. Approximately 70% of mice from HER2+ LMD and 30% from TNBC LMD demonstrated complete responses. This was CD4+ T cell dependent. Notably, cured mice also showed signs of resistance against LMD recurrence upon rechallenge. Subsequent single cell RNA-seq (scRNA-seq) analyses of the CSF showed a shift in the innate immune landscape found in untreated LMD to an adaptive immune landscape. In addition, we noted the elevated secretion of Th1 proinflammatory cytokines such as IFN-γ in the CSF. This was recapitulated in the CSF samples of patients enrolled in an on-going phase 1 trial, where early data showed IT cDC1 triggered a high concentration of several proinflammatory cytokines. Conclusions: Our preclinical data suggest IT cDC1 vaccine is effective against BC-LMD and prevents LMD recurrence. We are currently investigating the mechanism(s) by which IT cDC1-initiates the CD4 Th1 adaptive immune response against LMD. By employing an scRNA-seq approach, we hope to further determine the roles of different immune cells and their subtypes in the CSF to IT cDC1s in mice and in patients. A future approach includes testing IT cDC1 platform in LMD from other cancers (e.g. melanoma etc.).

A correlator sensor chip based on the integration of meta-materials and photonic crystals

More efficient induction of antitumor T cell immunity by exosomes from CD40L gene-modified lung tumor cells.

TGF-β1-silenced leukemia cell-derived exosomes target dendritic cells to induce potent anti-leukemic immunity in a mouse model

Efficacy of Intrathecal Delivery of Peptide-Pulsed Type 1 Conventional Dendritic Cell Vaccine for the Treatment of Breast Cancer-Associated Leptomeningeal Disease in Preclinical Models.

Enhanced induction of dendritic cell maturation and HLA-A*0201-restricted CEA-specific CD8 + CTL response by exosomes derived from IL-18 gene-modified CEA-positive tumor cells

Superior Anti-Tumor Protection and Therapeutic Efficacy of Vaccination with Dendritic Cell/Tumor Cell Fusion Hybrids for Murine Lewis Lung Carcinoma

[Association of three polymorphisms in the 3' untranslated region of the HLA-G gene with systemic lupus erythematosus in a population from Yunnan].

The Biological Characteristics of Dendritic Cells Derived in Vitro from Myelogeneous Leukemia Cells and Healthy Donor Cells.

Lymphotactin Gene-Modified Bone Marrow Dendritic Cells Act As More Potent Adjuvants for Peptide Delivery to Induce Specific Antitumor Immunity

Enhanced Therapeutic Efficacy Of Tumor Rna-Pulsed Dendritic Cells After Genetic Modification With Lymphotactin

Tumor Cell-associated Exosomes Robustly Elicit Anti-tumor Immune Responses through Modulating Dendritic Cell Vaccines in Lung Tumor

Efficient activation of antitumor immunity by IL-6 gene-modified leukemia vaccine in combination with low dose cyclophosphamide and low dose IL-2

More Than Chemotaxis: A New Anti-Tumor DC Vaccine Modified by Raav2-Slc

DC-Based Vaccines for Cancer Immunotherapy

Lymphotactin cotransfection enhances the therapeutic efficacy of dendritic cells genetically modified with melanoma antigen gp100

DC-Derived Exosomes for Cancer Immunotherapy

Dual effect of DLBCL-derived EXOs in lymphoma to improve DC vaccine efficacy in vitro while favor tumorgenesis in vivo

HLA-A2.1-restricted ECM1-derived epitope LA through DC cross-activation priming CD8+ T and NK cells: a novel therapeutic tumour vaccine

The construction of a lymphoma cell-based, DC-targeted vaccine, and its application in lymphoma prevention and cure

Intratumoral Administration of Immature Dendritic Cells Following the Adenovirus Vector Encoding CD40 Ligand Elicits Significant Regression of Established Myeloma

Co-delivery of Tumor-Derived Exosomes with Alpha-Galactosylceramide on Dendritic Cell-Based Immunotherapy for Glioblastoma